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Abstract
Use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is associated 
with dramatic, durable, and tolerable responses and side effect profiles when applied for palliation 
of advanced EGFR-mutated non-small-cell lung cancers (NSCLCs). Expert guidelines recommend 
that EGFR mutation testing results should be available within 10 working days of receipt of tumor 
specimen by the testing laboratory; in circumstances where the tumor specimen needs to be sent to 
an external laboratory for testing, the sample should be sent within 3 working days of receiving the 
request for testing. We report here 2 cases, out of 109 EGFR-mutated (exon 19 deletion or L858R) 
NSCLCs seen at our institution, experiencing rapid clinical deterioration and death within the 
window of time prescribed by consensus testing guidelines. We hypothesize that a faster turn-
around time may have changed the clinical outcome. Improving rapid turnaround times for tumor 
genotyping may afford more optimal palliation vis-à-vis early initiation of oral targeted therapy in 
patients with advanced EGFR-mutated NSCLC.
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Introduction
In 2013, the International Association for the Study of Lung Cancer (IASLC), Association 
for Molecular Pathology (AMP), and College of American Pathologists (CAP) published 
guidelines for molecular testing of epidermal growth factor receptor (EGFR) mutations and 
anaplastic lymphoma kinase (ALK) gene rearrangements in advanced lung adenocarcinomas 
(LACs). Expert consensus calls for EGFR mutation (exon 19 deletions and L858R genotype) 
and ALK rearrangement results to be available within 10 working days of receipt of tumor 
specimen by the testing laboratory; if send out testing is required, the specimen should be 
submitted to the outside vendor within 3 working days of receiving the request for testing1. 
It is unknown if a shorter turn-around time would impact outcomes of patients with 
advanced LAC.
Here, we report two cases of rapidly fatal LACs harboring sensitizing EGFR mutations. 
Patients seen at Beth Israel Deaconess Medical Center whose tumors were genotyped were 
identified through an ongoing Institutional Review Board-approved protocol2; 109 cases 
with EGFR exon 19 deletions (n=65) or L858R (n=44) were identified. Median overall 
survival was 37.6 months (95%CI 29.9-45.3) for advanced LACs (n =89). Of these, 2 (2.2%) 
patients died within 28 days of tissue diagnosis.
Discussion
Case Presentation #1
A previously healthy 59-year-old white female and non-smoker presented with 3 months of 
cough and dyspnea, subsequently developing acute headaches and intermittent confusion 
over one week. Imaging studies showed a left upper lung mass and multiple brain 
metastases. Eastern Cooperative Oncology Group (ECOG) performance status (PS) at 
presentation was 1. Transbronchial biopsy was performed (day 0), and final pathologic 
report showed LAC (day 4). A request for tumor genotyping (EGFR sequencing and ALK 
FISH) was placed (day 8), and tissue was submitted to an outside vendor (received on day 
10). The patient completed palliative whole brain radiotherapy (3000cGy) during this 
interim. PS was noted to have declined to 3, precluding cytotoxic chemotherapy. On day 8, 
she suffered further abrupt clinical deterioration (PS of 4) due to encephalopathy. 
Cerebrospinal fluid analysis confirmed malignant leptomeningeal involvement. Refractory 
encephalopathy led to withdrawal of care on day 16, and the patient died on day 22. A 
finalized report disclosing the EGFR genotype was received on the same day as death (day 
22), showing a sensitizing exon 19 deletion (E746_A750, Figure 1A).
Case Presentation #2
A 58 year-old gentleman with a 30 pack-year tobacco history presented with 2 months of 
progressive dyspnea and PS of 2. Imaging studies demonstrated a large right-sided 
mediastinal mass causing superior vena cava (SVC) obstruction, pleural, and pericardial 
effusions. Pericardial fluid cytology (day 0) revealed LAC (final report on day 5). A request 
for genomic testing was made (day 6), and the sample was received by the offsite vendor 
(day 8). Due to unstable clinical status, cytotoxic chemotherapy could not be initiated. 
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Pericardiocentesis, thoracentesis, SVC stenting, and tracheal stenting with intra-bronchial 
tumor debridement were performed, but the patient suffered respiratory failure with further 
decline in PS to 4 by day 5. He required ventilator support and died on day 9. A finalized 
report disclosing the EGFR genotype was received on day 20, showing a sensitizing exon 21 
L858R mutation (Figure 1B).
Conclusions
Cases of rapidly fatal (within the first month following a diagnostic procedure) EGFR-
mutated LAC were rare (<2%) in our cohort. In most circumstances, testing turnaround 
times (TATs) within the window currently endorsed by expert groups will allow for timely 
and efficacious care. We also note that testing paradigms may differ in various cancer 
centers/care settings, i.e. internal testing (which may offer more rapid results as compared to 
send-out testing). In those cases where patients are progressing rapidly and cannot wait for 
molecular testing results (but are otherwise appropriate candidates for cytotoxic 
chemotherapy), systemic therapy should not be withheld; patients can be transitioned to 
targeted therapies either once molecular data is known or upon completion of the planned 
initial course of chemotherapy3.
However, the experiences reported here highlight instances in which the current approach 
may hinder care in a small subset of patients with advanced disease, i.e. those (as in the 
patients presented here) in whom use of cytotoxic chemotherapies is precluded by 
inadequate clinical/performance status. Here, rapid knowledge of sensitizing oncogenic 
driver mutations may afford treatment with a relatively nontoxic, highly efficacious therapy 
within a narrow therapeutic window—and use of such agents in those with poor 
performance status (PS 3-4) is supported by evidence-based guidelines3 Despite tumor 
submission, testing, and reporting periods that fall within the timelines endorsed by expert 
groups1,4, the current strategy may provide results too late for therapeutic intervention in 
these circumstances.
Availability of point-of-care (POC) genomic testing may allow for rapid initiation of EGFR 
TKIs (gefitinib, erlotinib, afatinib), which are associated with initial rapid tumor regression 
in almost all cases of EGFR exon 19 deletion or L858R-mutated LACs5,6. It is therefore 
speculative to consider whether the patients presented here may have had more favorable 
outcomes if EGFR-targeted therapy had commenced soon after diagnosis. We propose POC 
testing with TATs in the 5-7 day range as an actionable target—the technology to 
accomplish this is being explored, but will take time to adequately develop for widespread or 
commercial use. Noninvasive genotyping methods using peripheral blood to assess either 
cell-free DNA (cfDNA) and/or circulating tumor cells (CTCs) are a rapidly evolving domain 
for improving the ease and rapidity of testing. In a recently published study, peripheral blood 
cfDNA testing with digital droplet PCR afforded rapid TATs (median 3 days) and with 
moderate sensitivity (69-80%)7; however, such technologies remain investigational for the 
time being. As such platforms evolve, maintaining precision while maximizing speed and 
accessibility will remain important priorities in the effort to optimally match patients with 
therapies.
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Figure 1. 
Tumor genotype procedures and timeframe. A.) Initial tissue sampling, genomic study 
request, arrival to vendor, issue of final report, and concise clinical course for case 1. B.) 
Initial tissue sampling, genomic study request, arrival to vendor, issue of final report, and 
concise clinical course for case number 2. Date of tissue acquisition in both cases = Day 0.
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